These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

171 related items for PubMed ID: 11362352

  • 1. Una conferencia de amnesia.
    Haas GJ.
    Common Factor; 1995 Apr; (no 10):30. PubMed ID: 11362352
    [Abstract] [Full Text] [Related]

  • 2. [Hemophilia and HTLV-III infection].
    Lechler E.
    Z Hautkr; 1986 Dec 01; 61(23):1687-704. PubMed ID: 2949442
    [Abstract] [Full Text] [Related]

  • 3. Recombinant factor VIII in hemophilia A: the Canadian experience.
    Blanchette VS.
    Blood Coagul Fibrinolysis; 1997 Aug 01; 8 Suppl 1():S33-9. PubMed ID: 9351535
    [Abstract] [Full Text] [Related]

  • 4. [New approaches to haemophilia treatment--recombinant and transgenic concentrates, gene therapy and engineered coagulation factors].
    Habart D.
    Cas Lek Cesk; 2006 Aug 01; 145(2):104-11. PubMed ID: 16521398
    [Abstract] [Full Text] [Related]

  • 5. Prevalence of IgG antibodies to human parvovirus B19 in haemophilia children treated with recombinant factor (F)VIII only or with at least one plasma-derived FVIII or FIX concentrate: results from the French haemophilia cohort.
    Gaboulaud V, Parquet A, Tahiri C, Claeyssens S, Potard V, Faradji A, Peynet J, Costagliola D, Suivi Thérapeutique National des Hémophiles Group.
    Br J Haematol; 2002 Feb 01; 116(2):383-9. PubMed ID: 11841442
    [Abstract] [Full Text] [Related]

  • 6. [Current status of viral safety of virus inactivated factor VIII and IX concentrates in treatment of hemophilia].
    Pollmann H.
    Infusionsther Transfusionsmed; 1994 Aug 01; 21 Suppl 1():80-3. PubMed ID: 8000261
    [Abstract] [Full Text] [Related]

  • 7. Defendants challenge class action certification.
    Dubin CS, Wadleigh J.
    Common Factor; 1995 Apr 01; (no 10):1, 33-36. PubMed ID: 11362336
    [Abstract] [Full Text] [Related]

  • 8. National Academy of Sciences convenes public hearing on HIV and the blood supply.
    Dubin CS.
    Common Factor; 1995 Apr 01; (no 10):4. PubMed ID: 11362355
    [Abstract] [Full Text] [Related]

  • 9. [Current status and future prospects of hemophilia treatment].
    Lopaciuk S.
    Acta Haematol Pol; 1995 Apr 01; 26(2 Suppl 1):44-55. PubMed ID: 7653234
    [Abstract] [Full Text] [Related]

  • 10. Effect of HIV-1 infection on CD4 cells in a hemophilia cohort.
    Green D, Deutsche J, Tang M, Goldsmith J.
    Haematologica; 1990 Apr 01; 75 Suppl 5():132-41. PubMed ID: 1982277
    [No Abstract] [Full Text] [Related]

  • 11. Dallas, police surveillance and the NHF. National Hemophilia Foundation.
    Dubin CS.
    Common Factor; 1995 Apr 01; (no 10):3, 31-2. PubMed ID: 11362351
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Makers of clotting medicine not entitled to liability shield.
    AIDS Policy Law; 1996 Feb 23; 11(3):7. PubMed ID: 11363179
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Advances in care of children with hemophilia.
    Manco-Johnson MJ, Riske B, Kasper CK.
    Semin Thromb Hemost; 2003 Dec 23; 29(6):585-94. PubMed ID: 14719175
    [Abstract] [Full Text] [Related]

  • 19. Factor products in the treatment of hemophilia.
    Miller KL.
    J Pediatr Health Care; 2004 Dec 23; 18(3):156-7. PubMed ID: 15129219
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.